Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...
Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback